Fundraising Fox

Biotheryx

San Diego, US · California corporation · 2 known investors

biotheryx.com ↗

Biotheryx discovers and develops targeted protein degrader drugs designed to treat cancer and inflammatory diseases. The company uses its proprietary PRODEGY platform to create molecular glues and bifunctional degraders, with lead programs in clinical trials for oncology indications including breast cancer and hematologic malignancies.

BiotechMedical Devicesin /biotheryx-inc.

Founders & leadership

KC
Kyle Chan, PhDExecutive Officer
DS
David Stirling, PhDExecutive Officer, Director
LD
Louis DeGennaro, PhDDirector
LZ
Lawrence ZaslowExecutive Officer, Director
FM
Frank Mercurio, PhDExecutive Officer

Investors · 2

Lumira VenturesToronto · $1M – $10M
SR One Capital ManagementRedwood City

Reported raises · per SEC filings

Form D private placements
▶$92.1MraisedJun 2021 · 40 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kyle W.H. ChanExecutive Officer
  • Dung ThaiExecutive Officer
  • Jack NoelkeDirector
  • Christopher DevineDirector
  • Jaime A. DonadioExecutive Officer
  • Louis DeGennaroDirector
  • David I. StirlingExecutive Officer, Director
  • Frank MercurioExecutive Officer
  • Robert F. WilliamsonExecutive Officer, Director
Offering amount
$100M
Amount sold
$92.1M
First sale
May 2021
Incorporated
Corporation, California
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$500KraisedMay 2015 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kyle Chan, PhDExecutive Officer
  • David Stirling, PhDExecutive Officer, Director
  • Louis DeGennaro, PhDDirector
  • Lawrence ZaslowExecutive Officer, Director
  • Frank Mercurio, PhDExecutive Officer
Offering amount
$6M
Amount sold
$500K
Minimum investment
$50K
First sale
Apr 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.